C-TRAIN News
Academic Cross-Training in Nanomedicine10/31/2007
NEW!
Nanotechnology offers new possibilities for dealing with old problems in diagnosing,
treating, and preventing cancer. To realize this potential, scientists from disparate
fields are collaborating on wide-ranging projects, bringing their different skills and
mindsets to the table. Research teams comprising engineers, chemists, biologists, surgeons,
and pathologists are becoming the norm in the cancer nanotechnology world, in large part
because of prompting and encouragement from the National Cancer Institute’s (NCI) Alliance
for Nanotechnology in Cancer.
Read More
Targeted Nanoparticles Image Early Tumors3/10/2007
NEW!
A well-established fact in cancer therapy is that early tumor detection improves the odds that
a patient will survive the disease. Now, using nanoparticles targeted to the tiny blood vessels that
surround even the smallest tumors, researchers at the Siteman Center for Cancer Nanotechnology Excellence
(CCNE) have developed a radioactive imaging agent that was able to identify human tumors in rabbits. This
work appears in the International Journal of Cancer.
Read More
Academic Cross-Training in Nanomedicine2/1/2007
NEW!
Nanotechnology offers new possibilities for dealing with old problems in diagnosing,
treating, and preventing cancer. To realize this potential, scientists from disparate fields are
collaborating on wide-ranging projects, bringing their different skills and mindsets to the table.
Research teams comprising engineers, chemists, biologists, surgeons, and pathologists are becoming
the norm in the cancer nanotechnology world, in large part because of prompting and encouragement
from the National Cancer Institute’s (NCI) Alliance for Nanotechnology in Cancer.
Read More
Nanotechnology enables low-dose treatment of atherosclerotic plaques8/11/2006
In laboratory tests, one very low dose of a drug was enough to have an effect on notoriously
tenacious artery-clogging plaques. What kind of drug is that potent? It's not so much the drug itself as how it was delivered. Fumagillin
— a drug that can inhibit the growth of new blood vessels that feed atherosclerotic plaques
— was sent directly to the base of plaques by microscopically small spheres called nanoparticles
developed by School of Medicine researchers.
Read More
$16 Million National Cancer Institute Award Advancing Nanomedicine Research in Cancer 10/3/2005
Nano-sized particles developed at Washington University School of Medicine in St. Louis offer hope of
replacing numerous medical tests, scans, or surgeries with a simple injection. The tiny spheres can
travel through the bloodstream deep into the body to locate and highlight tumors undetectable by typical
methods. While at the tumor site, the nanoparticles can deliver therapeutic agents to destroy the tumor.
To advance this promising technology, the National Cancer Institute (NCI) has awarded $16 million over
five years to the School of Medicine to establish the Siteman Center of Cancer Nanotechnology Excellence
(SCCNE). The NCI also awarded funding for six other Centers of Cancer Nanotechnology Excellence (CCNEs)
around the United States.
Read More